Nika Pharmaceuticals Completes Acquisition
Ticker: NIKA · Form: 8-K · Filed: Aug 27, 2024 · CIK: 1145604
| Field | Detail |
|---|---|
| Company | Nika Pharmaceuticals, Inc (NIKA) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, corporate-event
TL;DR
Nika Pharma just closed a deal, watch this space.
AI Summary
Nika Pharmaceuticals, Inc. announced the completion of an acquisition on August 18, 2024. The company, formerly known as Centennial Growth Equities Inc., is headquartered in Henderson, NV. The filing was made on August 27, 2024.
Why It Matters
This filing indicates a significant corporate event for Nika Pharmaceuticals, potentially impacting its business strategy and future growth.
Risk Assessment
Risk Level: medium — Acquisitions can introduce integration challenges and financial risks, but the specific details of this deal are not yet fully disclosed.
Key Players & Entities
- NIKA PHARMACEUTICALS, INC. (company) — Registrant
- CENTENNIAL GROWTH EQUITIES INC (company) — Former Company Name
- 20240818 (date) — Date of earliest event reported
- 20240827 (date) — Filing Date
- 7023263615 (phone_number) — Business Phone
- 2269 MERRIMACK VALLEY AVENUE (address) — Business Address
- HENDERSON, NV 89044 (address) — Business Address
FAQ
What was the nature of the acquisition completed by Nika Pharmaceuticals?
The filing indicates the completion of an acquisition or disposition of assets, but specific details are not provided in this excerpt.
When did Nika Pharmaceuticals officially complete this acquisition?
The earliest event reported, which is the completion of the acquisition, occurred on August 18, 2024.
What was Nika Pharmaceuticals' former name?
Nika Pharmaceuticals, Inc. was formerly known as Centennial Growth Equities Inc.
Where is Nika Pharmaceuticals, Inc. located?
The company's principal executive offices are located at 2269 Merrimack Valley Avenue, Henderson, NV 89044.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed on August 27, 2024.
Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-08-27 16:30:15
Filing Documents
- form8k.htm (8-K) — 14KB
- exhibit23-1.htm (EX-23) — 5KB
- exhibit23-1x1x1.jpg (GRAPHIC) — 1KB
- exhibit23-1x1x2.jpg (GRAPHIC) — 2KB
- exhibit23-1x1x3.jpg (GRAPHIC) — 2KB
- 0001826466-24-000096.txt ( ) — 190KB
- nkph-20240818.xsd (EX-101.SCH) — 3KB
- nkph-20240818_lab.xml (EX-101.LAB) — 33KB
- nkph-20240818_pre.xml (EX-101.PRE) — 22KB
- form8k_htm.xml (XML) — 3KB
01 Completion of Acquisition of Assets
Item 2.01 Completion of Acquisition of Assets. On August 18, 2024, based on recommendation of Clifford Redekop, officer and director, the board of directors found it in the Nika Pharmaceuticals Inc.s best interest to cancel the acquisition of Nika Pharmaceuticals, Ltd., UIC: 175420503 that was made effective on May 9, 2024 and disclosed via Form 8-K on May 10, 2024. The procedure to return the 100% to Dimitar Slavchev Savov, who is an officer and director of Nika Pharmaceluticals, Inc. and general manager of Nika Pharmaceuticals, Ltd., was initiated on August 19, 2024 and was made effective on August 23, 2024, resulting in Nika Pharmaceuticals, Ltd. no longer being a wholly owned subsidiary of Nika Pharmaceuticals, Inc. As a result, Nika Pharmaceuticals, Inc. no longer practically owns 99.99% in Nika Europe, Ltd. and is no longer the beneficial dated May 10, 2024. Section 4 - Matters Related to Accountants and Financial On August 21, 2024 Nika Pharmaceuticals, Inc.s independent accountant Fruci & Associates II, PLLC tendered its resignation. The members of the board of directors have discussed the issue with the former independent accountant, and Nika Pharmaceuticals, Inc. has authorized the former independent accountant to respond fully to the inquiries of the successor accountant concerning historical data. As the situation was unexpected, Nika Pharmaceuticals, Inc. is still looking for a new firm to serve as the independent accountant to audit the companys financial statements and will strive to publish its 10-Q as early as possible.
01 Exhibits
Item 9.01 Exhibits (d) Exhibits 23.1 Consent Letter by Fruci & Associates II, PLLC
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized. NIKA PHARMACEUTICALS, INC. Dated: August 27, 2024 By: /s/ Dimitar SlavchevSavov Dimitar SlavchevSavov Chief Executive Officer, Director